Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non–insulin dependent diabetes mellitus
A serial intravascular ultrasound study
Tsutomu Takagi, MDa,
Takashi Akasaka, MDa,
Atsushi Yamamuro, MDa,
Yasuhiro Honda, MDa,
Takeshi Hozumi, MDa,
Shigefumi Morioka, MDa and
Kiyoshi Yoshida, MD, FACCb
a Division of Cardiology, Kobe General Hospital, Minatojima Nakamachi 4-6, Chuo-Ku, Kobe, Japan
b Division of Cardiology, Department of Internal Medicine, Kawasaki Medical University, Kurashiki, Japan
View larger version (25K):
[in a new window]
|
Figure 1 Plasma glucose levels and insulin levels during the OGTT. No significant differences were observed in fasting plasma glucose levels and plasma glucose levels at 1 and 2 h after the glucose load between troglitazone group and control group at baseline (top, left). However, plasma glucose levels at 1 and 2 h after the glucose load in troglitazone group were significantly smaller than those in control group at follow-up (top, right). No significant differences existed in fasting insulin levels and insulin levels at 1 and 2 h after the glucose load between two groups at baseline (bottom, left). However, fasting insulin levels and insulin levels at 1 and 2 h after the glucose load in troglitazone group were significantly smaller than were those in control group at follow-up (bottom, right). Closed circle = troglitazone group; open circle = control group. *p < 0.05 vs. control group.
|
|
View larger version (22K):
[in a new window]
|
Figure 2 Cumulative distribution curves of minimal lumen diameter (MLD) at preintervention, at postintervention, and at follow-up. Closed circle, closed square, and closed triangle demonstrate MLD in troglitazone group at preintervention, at postintervention, and at follow-up, respectively. Open circle, open square, and open triangle demonstrate MLD in control group at preintervention, at postintervention, and at follow-up, respectively.
|
|
|
